Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry...

2019-12-20 10:19 1283

Specialised Therapeutics Signs Exclusive Deal for New Haematology Drug

SINGAPORE, Dec. 18, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with US-based Onconova Therapeutics (NASDAQ: ONTX), securing commercialisation rights to a new therapy for the treatment of Myelodysplastic Syndrome...

2019-12-18 22:00 2783

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment ofJie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters inShanghai, China. Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and ...

2019-12-18 00:00 1970

iX Biopharma Reports on Outcome of Wafermine End-of-phase 2 Meeting with US FDA

SINGAPORE, Dec. 11, 2019 /PRNewswire/ -- Specialty pharmaceutical company iX Biopharma Ltd(SGX:42C) ("iX Biopharma" or, "the Company") is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublin...

2019-12-11 22:00 1949

Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies

SUZHOU, China and SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American...

2019-12-09 22:00 1391

Hebron Announces $6.5 Million Private Placement

WENZHOU, China, Dec. 9, 2019 /PRNewswire/ -- Hebron Technology Co., Ltd. (" Hebron" or the "Company") (Nasdaq: HEBT), a developer, manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverage, and other clean industries, today announced that ...

2019-12-09 21:30 2276

BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors

HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the 'company') today announced that the first patient was successfully dosed on December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001 program at NEXT ONCOLOGY inSan Antonio, Texas.

2019-12-09 21:00 1550

BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors

Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US

TAIPEI, Dec. 3, 2019 /PRNewswire/ -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain®) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain...

2019-12-03 17:36 1116

New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority

* NERLYNX® (neratinib) now approved in Singapore for HER2+ breast cancer patients following adjuvant trastuzumab-based therapy * NERLYNX is the first therapy in the Specialised Therapeutics' portfolio approved inSE Asia * Five-year follow up data show NERLYNX reduces risk of invasive disease...

2019-12-03 05:30 1200

Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly

SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (01801.HK), a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal anti...

2019-12-02 09:37 5287

1 ... 122 123 124 125126

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 283 media titles]

2024-11-20 09:00